LBBM CRO Contract Research Organization
LBBM Biomedical Research
History of LBBM Research Clinical Trials
Staff of LBBM Bioequivalence
LBBM Quality Assurance
LBBM Contact CRO
Clinical Trial Research in Argentina
Pharmacokinetic Studies
Biomedical research Clinical Trial protocol writing Clinical Trials CRO Site Selection Drug distribution in Clinical Trials Biotechonolgy LBBM Bioanalisis Auditing Consultancy Clinical Research Trials
<h1>CRO In Argentina, Latin America</h1> <h2>CRO South America</h2> <ul> <li>cro argentina</li> <li>cro africa</li> <li>cro brazil</li> <li>cro canada</li> <li>cro china</li> <li>cro europe</li> <li>cro india</li> <li>cro japan</li> <li>cro latinamerica</li> <li>cro mexico</li> <li>cro southamerica</li> <li>cro us</li> <li>cro usa</li> </ul>


The main advantages of performing a trial in Argentina include location, excellence, demographics and costs:


  • Argentina has around 39 million inhabitants, 30% of the population lives in Buenos Aires downtown and suburbs (around 13 millions), facilitating communication with many sites and study medication distribution
  • The provinces of Argentina have important cities concentrating a huge population of patients of the whole area (Mendoz:,0.93 mio, Córdoba: 1.5 mio, Rosario-Santa Fe:1.8mio, Mar del Plata: 0.6mio, Tucumán: 0.84 mio, La Plata:0.78 mio)
  • Argentina is part of Mercosur (together with Brasil, Paraguay and Uruguay, Perú, Bolivia and Chile are associated), facilitating the exchange with these countries also on a regulatory level.


  • Argentina has an important scientific tradition with expertise investigators
  • Argentina Ministry of Health through its National Administration of Drugs and Food Technology (ANMAT) has a large experience on evaluating international trials (since 1993) and assures strict adherence to ICH-GCP guidelines meeting the regulatory standards of EMEA and FDA.
  • In the scientific environment, english is the common language and understood by all professionals


  • Patient population: large patient population available and willing to participate in a trial
  • Special populations (pediatric, gerontology, psychiatric, HIV naïve patients, etc)
  • Ethnic similarity to European population due to the immigration phenomenon (70-80% of the population )
  • High degree of alphabetization (97.1%, 2001), avoiding regulatory issues concerning informed consent comprehension.

The costs in Argentina are significantly lower than for USA and Europe:

  • Investigator fees
  • Project management and monitoring fees
  • Laboratory costs and additional studies (imaging, substudies)
  • Additional pass-through costs such as travel, accommodation, courier, etc


llbm Once you need to decide which countries should be involved in your trial, you should consider Argentina, a huge country in the most southern extreme of America, with around 40mio inhabitants and a very good health system ranking, locating us above many eastern Europe countries in position 49 under 191 countries according to the WHO overall health system attainment report. llbm